The patient's presentation with an acute, severe hepatocellular injury pattern shortly after exposure to a new medication known to cause hepatotoxicity is highly characteristic of drug-induced liver injury (DILI). Nitrofurantoin is a well-known cause of both acute and chronic DILI. The exclusion of other common causes of acute hepatitis (viral, autoimmune) further supports this diagnosis. Acute cholangitis would present with fever and a cholestatic picture. Ischemic hepatitis occurs in settings of hemodynamic instability.

This patient's presentation of a middle-aged woman with fatigue, pruritus, xanthelasmas, a cholestatic pattern of liver injury (markedly elevated alkaline phosphatase with near-normal transaminases), and a positive anti-mitochondrial antibody (AMA) is classic for primary biliary cholangitis (PBC). AMA is highly specific for PBC, found in about 95% of patients.

The patient's symptoms, recent travel to an endemic area, and acute hepatocellular injury pattern are highly suggestive of acute hepatitis A. The diagnosis of acute hepatitis A is confirmed by the presence of IgM anti-HAV antibodies. IgG anti-HAV indicates prior infection or immunization and confers immunity. HBsAg and anti-HCV are markers for hepatitis B and C, respectively.

All patients with cirrhosis, regardless of etiology or compensation status, are at increased risk for developing hepatocellular carcinoma (HCC) and should undergo routine surveillance. The standard recommendation by major society guidelines is screening with an abdominal ultrasound every 6 months. Serum alpha-fetoprotein (AFP) may be used as an adjunct to ultrasound but is not recommended as a standalone screening test due to poor sensitivity and specificity. More frequent screening or annual CT scans are not the standard of care.

This patient exhibits both physical stigmata (spider angiomata, palmar erythema) and laboratory evidence (thrombocytopenia, elevated INR, hypoalbuminemia) of cirrhosis, which reflects impaired hepatic synthetic function and portal hypertension. Cirrhosis is defined as compensated when these features are present without overt clinical decompensating events such as variceal hemorrhage, ascites, or hepatic encephalopathy. Since the patient denies these complications, her condition is best described as compensated cirrhosis.

This patient is presenting with overt hepatic encephalopathy (HE), likely precipitated by constipation. The first-line treatment for HE is lactulose, a non-absorbable disaccharide. It works by acidifying the gut to trap ammonia as non-absorbable ammonium and by promoting its cathartic removal. Rifaximin is an effective second-line agent, typically added to lactulose in patients with recurrent HE. Propranolol is used for variceal prophylaxis, and furosemide is used for ascites management.

This patient has multiple components of the metabolic syndrome (obesity, diabetes, hyperlipidemia), which are major risk factors for nonalcoholic fatty liver disease (NAFLD). The typical laboratory pattern for NAFLD is a mild to moderate elevation of aminotransferases with an AST:ALT ratio of less than 1, which is seen in this case. His minimal alcohol intake makes alcoholic liver disease unlikely, which also typically presents with an AST:ALT ratio >2. Autoimmune hepatitis usually has much higher aminotransferase levels, and Wilson disease is a rare genetic disorder typically presenting in younger individuals.

This patient meets the diagnostic criteria for hepatorenal syndrome type 1 (HRS-AKI), a functional renal failure due to severe splanchnic and systemic vasodilation in advanced cirrhosis. The standard of care for treatment is the combination of albumin with splanchnic vasoconstrictors. The most commonly used regimen is midodrine (an oral alpha-1 agonist) and octreotide (a somatostatin analog). Norepinephrine can be used in an ICU setting. Diuretics are contraindicated as they would worsen intravascular volume depletion. Antibiotics would be indicated if an infection like SBP was the trigger, but are not the primary treatment for HRS itself.

This patient presents with asymptomatic, mild, unconjugated (indirect) hyperbilirubinemia, exacerbated by stress. This is the classic presentation of Gilbert syndrome, a benign inherited disorder of bilirubin conjugation due to reduced activity of the UGT1A1 enzyme. The key features are isolated unconjugated hyperbilirubinemia with otherwise normal liver function tests and no evidence of hemolysis. Crigler-Najjar is a more severe conjugation defect. Dubin-Johnson and Rotor syndromes cause conjugated hyperbilirubinemia. Acute viral hepatitis would cause significantly elevated aminotransferases.

The patient's presentation of a young woman with a significant hepatocellular injury pattern, arthralgias, and hypergammaglobulinemia (indicated by the elevated total protein with normal albumin, known as the globulin gap) is highly suggestive of autoimmune hepatitis (AIH). The diagnosis of type 1 AIH is supported by the presence of autoantibodies, most commonly anti-nuclear antibodies (ANA) and/or anti-smooth muscle antibodies (ASMA). Anti-mitochondrial antibodies are for PBC. Low ceruloplasmin suggests Wilson disease. Elevated iron studies suggest hemochromatosis.